Atezolizumab with mFOLFOX6 Boosts 3-Year DFS by 10.1% in Stage III dMMR Colon Cancer
Could a New Treatment Boost Survival for Stage III Colon Cancer Patients?
In a phase 3 trial, atezolizumab plus mFOLFOX6 improved 3-year disease-free survival to 86.3% vs. 76.2% with mFOLFOX6 alone (HR 0.50; 95% CI…
Adding atezolizumab to standard chemotherapy boosted 3-year disease-free survival to 86% in stage III colon cancer patients, up from 76% wit…
CSF ctDNA Status Predicts Survival in Leptomeningeal Metastases: Meta-Analysis
Can a Simple Test in Spinal Fluid Predict Survival for Cancer Patients?
In a meta-analysis of 14 studies (n=963), adverse baseline CSF ctDNA status was linked to worse OS (HR 2.40, 95% CI 1.73-3.33) and PFS (HR 2…
A simple spinal fluid test can predict how long someone with advanced cancer might live by spotting DNA markers linked to shorter survival t…